The High-Content Screening short course is designed to provide the framework, skills and knowledge to assist participating organizations in setting up a high-content screening capability in their lab.
Under the guidance of a skilled instructor, participants will learn topics including infrastructure requirements, image acquisition and data analytics, developing high-content assays, and running high-content screens.
Completion of this course will grant participants the ability to:
Cost: $10,000
Price includes travel and lodging costs for the course instructor.
Availability
This course can be conducted onsite at a host institution or it can be conducted virtually.
Note: Course scheduling is dependent on the instructors’ availability. Please request the High-Content Screening short course on demand at your earliest convenience so that we may best accommodate your requested date(s).
If you would like to conduct this course at your institution, please email SLAS Scientific Manager Hannah Rosen, Ph.D.
James Pilling, Ph.D.: Associate principal scientist at AstraZeneca.
Niamh Mullooly, Ph.D.: Niamh Mullooly, Ph.D., joined AstraZeneca as a senior research scientist in the High-Content Biology team. In this position, she developed high-content assays and conducted screening campaigns to support drug discovery projects. The team's remit changed to a Functional Genomics-led focus due to the identification of an opportunity to apply high-content imaging and automation to arrayed CRISPR screening for target identification and validation. After seven years at AstraZeneca, she left to join the TechBio company Healx where she established an automation-led laboratory to generate richly annotated large data sets for incorporation into the company's rare disease knowledge graph for AI/ML interrogation. At Healx she also led activities to gain an understanding of rare disease biology at scale through arrayed CRISPR screening coupled with high-content omics endpoints. Mullooly recently joined Novo Nordisk as a principal scientist in the company's “Target Discovery Engine” where she will support novel target discovery through functional genomics and high-content phenotypic screening.
Sinead Knight, Ph.D.: Principal scientist at Sygnature Discovery.
Our team of instructors is comprised of industry experts skilled in high-content cellular imaging, developing assays for high-content screening, the platforms and infrastructure required for high-content screening and other areas of laboratory expertise, as well as teaching and educational experience.
Thierry Dorval, Ph.D. (France): Thierry Dorval received a Ph.D. in image analysis and artificial intelligence from the University Pierre & Marie Curie and then joined the Institut Pasteur Korea in 2005 as a group leader specializing in high-content screening applied to cellular differentiation and toxicity prediction. In 2012 he joined AstraZeneca, where his activities were about developing and advising on quantitative image and data analysis solutions in support of high-content phenotypic screening. Finally, in 2015 he joined Servier, France, to lead the data sciences & data management pole of activities where he is in charge of optimizing the early stages of drug discovery by taking advantage of cutting-edge computational approaches.
Samantha Peel, Ph.D. (United Kingdom): Senior director at AstraZeneca.
